Healthcare Industry News: immunotherapy
News Release - August 14, 2017
MaxCyte Appoints Executive Vice President of Global Marketing25-year biopharma industry veteran joins the Company to drive further growth of its innovative high-performance cell engineering platform for use in commercial drug development
GAITHERSBURG, Md., Aug. 14, 2017 -- (Healthcare Sales & Marketing Network) -- MaxCyte, a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today that it has appointed Brad Calvin, a 25-year veteran within the drug development and biotechnology industries, as Executive Vice President of Global Marketing. In his role, Mr. Calvin is responsible for leading MaxCyte's marketing function to drive growth of the Company's drug discovery and cell therapy business.
Doug Doerfler, Chief Executive Officer, said, "We are delighted to have someone of Brad's caliber join MaxCyte to lead our marketing and market development efforts. Brad's broad biopharmaceutical industry experience has provided him with an in-depth understanding of working across global markets and supporting all phases of product life cycles. His appointment comes at an opportune time for the Company, as we continue to develop new offerings based on our Flow Electroporation® Technology."
Mr. Calvin was most recently Co-founder and President of AsedaSciences, a company with an integrated technology platform to predict in vivo toxicity risk in early-stage drug discovery. Previously, he has held various leadership positions at companies ranging from large corporations to start-ups, such as Accuvein, Beckman Coulter, Qiagen, Digene, AGENIX, and Abbott Laboratories. He has a Bachelor's degree from Curtin Institute of Technology in Perth, Western Australia.
"MaxCyte's proprietary technology uniquely positions the Company as an enabler for the preclinical, clinical and commercial application of cutting-edge treatments across a broad range of classes of medicines including immuno-oncology and gene editing," said Mr. Calvin. "I've been impressed with the expertise, dedication and talent of the MaxCyte team, and of the support they provide to companies working to develop the most advanced cell-based medicines, which are desperately needed to address difficult-to-treat diseases and disorders. I look forward to helping to advance our collaborations and enhancing the value of our commercial partnerships."
MaxCyte is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.
For more information, visit http://www.maxcyte.com/
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.